I believe these two small-cap growth stocks can make you famously rich

These two small-caps are well placed to profit from healthcare trends.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Oncimmune Holdings (LSE: ONC) has only been a public company for a year-and-a-half, but during that time the firm has made a significant impact. 

And as it continues to develop its product offering, manufacturing new devices as well as expanding into new markets, I believe that it could produce enormous returns for investors. 

Gearing up for growth 

The company, which is focused on early cancer detection, is on track to begin shipping its leading product, the EarlyCDT-Lung kit in the next few weeks. Management has already signed distribution agreements with several countries for this equipment. Minimum payment guarantees of £6.1m from its Asian partners and £1.4m from European partners over the next four to five years have been confirmed. 

As well as its early detection kit for lung cancer, the firm is working towards receiving approvals for its EarlyCDT-Liver test and EarlyCDT-Ovarian test. Further progress on these two initiatives should be announced next year. 

Huge rewards 

The fiscal year ended 31 May was a transformational one for the company. Even though revenue generated was only £0.22m, the approval of the EarlyCDT-Lung kit received in May 2017 means that management can now begin to focus on sales growth. 

To help fund this expansion, the company raised £5m via a placing at the end of September. According to CEO Geoffrey Hamilton-Fairley: “With a strong team in place, a fundraising completed and our R&D progressing well the board is increasingly confident that the Company is well placed to execute that plan and deliver value in the medium and long term.” 

As of yet, there no City analyst has come up with growth projections for Oncimmune, but if the company’s products do what they say, the potential could be enormous. 

Five-year survival for lung cancer, the most prominent cancer killer, averages around 17% for all stages, but for patients diagnosed early, the five-year survival rate is as high as 90%. So the benefits (both financial and ethical) on offer if the company succeeds should be tremendous. 

Bouncing back

CareTech Holdings (LSE: CTH) is another health sector growth champion that I believe has the potential to produce huge returns for investors. It is a provider of social care services. Unfortunately, the company has recently sailed into stormy waters and earnings per share are expected to have fallen by 11% for the fiscal year ended 30 September. Excluding this blip, earnings per share had grown by 39% in four years. 

Going forward, it looks as if CareTech is going to get back on track. Analysts have pencilled in earnings per share growth of 7% for 2018, and pre-tax profit is on track to hit an all-time high. 

To help drive growth, during June management agreed to acquire the entire issued share capital of Selborne Care for a total consideration of £16.9m in cash. It is believed that this deal will be immediately earnings enhancing, growing both the top and bottom lines of the combined group and management is looking for further deals to bolt-on growth. 

As the shares currently trade at a forward P/E of 11.4 and yield 2.5%, I believe that investors can buy into this growth story at an attractive valuation. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no position in any stock mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Shot of a young Black woman doing some paperwork in a modern office
Investing Articles

With an 8% dividend yield, I think this undervalued FTSE stock is a no-brainer buy

With an impressive yield and good track record of payments, Mark David Hartley is considering adding this promising FTSE share…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

£9,500 in savings? Here’s how I’d try to turn that into £1,809 a month of passive income

Investing a relatively small amount into high-yielding stocks and reinvesting the dividends paid can generate significant passive income over time.

Read more »

Businesswoman analyses profitability of working company with digital virtual screen
Investing Articles

Dividend star Legal & General’s share price is still marked down, so should I buy more?

Legal & General’s share price looks very undervalued against its peers. But it pays an 8%+ dividend yield, and has…

Read more »

Investing Articles

Dividend shares: 1 FTSE 100 stock to consider buying for chunky shareholder income

This company’s ‘clean’ dividend record looks attractive to me and I’d consider buying some of the shares to hold long…

Read more »

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »